155 related articles for article (PubMed ID: 7721118)
1. Efficacy of apraclonidine ophthalmic solution (Iopidine) in presumed silicon oil-induced glaucoma and primary open-angle glaucoma.
Gramer E; Busche S; Kampik A; Parsons D
Graefes Arch Clin Exp Ophthalmol; 1995 Jan; 233(1):13-20. PubMed ID: 7721118
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of apraclonidine ophthalmic solution (iopidine) in presumed silicon oil-induced glaucoma and primary open-angle glaucoma.
Flach AJ
Surv Ophthalmol; 1995; 40(1):84-5. PubMed ID: 8545811
[No Abstract] [Full Text] [Related]
3. Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.
Robin AL; Ritch R; Shin D; Smythe B; Mundorf T; Lehmann RP
Trans Am Ophthalmol Soc; 1995; 93():421-38; discussion 439-41. PubMed ID: 8719690
[TBL] [Abstract][Full Text] [Related]
4. The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients.
Konstas AG; Maltezos A; Mantziris DA; Sine CS; Stewart WC
Eye (Lond); 1999 Jun; 13 ( Pt 3a)():314-8. PubMed ID: 10624424
[TBL] [Abstract][Full Text] [Related]
5. Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study.
Nagasubramanian S; Hitchings RA; Demailly P; Chuniaud M; Pannarale MR; Pecori-Giraldi J; Stodtmeister R; Parsons DG
Ophthalmology; 1993 Sep; 100(9):1318-23. PubMed ID: 8371918
[TBL] [Abstract][Full Text] [Related]
6. Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group.
Robin AL; Ritch R; Shin DH; Smythe B; Mundorf T; Lehmann RP
Am J Ophthalmol; 1995 Oct; 120(4):423-32. PubMed ID: 7573299
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
[TBL] [Abstract][Full Text] [Related]
8. Reversal of intraocular pressure increases with 0.5% apraclonidine after dilated fundus examination in patients with chronic open-angle glaucoma.
Nishimoto JH; Chang FW; Tang IH; Kolin T
J Am Optom Assoc; 1999 Apr; 70(4):233-9. PubMed ID: 10457699
[TBL] [Abstract][Full Text] [Related]
9. Chronic use of apraclonidine decreases its moderation of post-laser intraocular pressure spikes.
Chung HS; Shin DH; Birt CM; Kim C; Lee D; Levin DS; Hakimzadeh R; Juzych MS
Ophthalmology; 1997 Nov; 104(11):1921-5. PubMed ID: 9373127
[TBL] [Abstract][Full Text] [Related]
10. The rarity of clinically significant rise in intraocular pressure after laser peripheral iridotomy with apraclonidine.
Lewis R; Perkins TW; Gangnon R; Kaufman PL; Heatley GA
Ophthalmology; 1998 Dec; 105(12):2256-9. PubMed ID: 9855156
[TBL] [Abstract][Full Text] [Related]
11. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group.
Stewart WC; Laibovitz R; Horwitz B; Stewart RH; Ritch R; Kottler M
Arch Ophthalmol; 1996 Aug; 114(8):938-42. PubMed ID: 8694728
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group.
Stewart WC; Ritch R; Shin DH; Lehmann RP; Shrader CE; van Buskirk EM
Arch Ophthalmol; 1995 Mar; 113(3):287-92. PubMed ID: 7887841
[TBL] [Abstract][Full Text] [Related]
13. Clonidine provides an allergy-free alternative in glaucoma patients with proven allergy to apraclonidine.
Geyer O; Schmidt KG; Pianka P; Neudorfer M; Lazar M
Graefes Arch Clin Exp Ophthalmol; 2000 Feb; 238(2):149-52. PubMed ID: 10766284
[TBL] [Abstract][Full Text] [Related]
14. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
Shin DH; Glover BK; Cha SC; Kim YY; Kim C; Nguyen KD
Am J Ophthalmol; 1999 May; 127(5):511-5. PubMed ID: 10334342
[TBL] [Abstract][Full Text] [Related]
15. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery.
Chen TC; Ang RT; Grosskreutz CL; Pasquale LR; Fan JT
Ophthalmology; 2001 Jun; 108(6):1033-8. PubMed ID: 11382625
[TBL] [Abstract][Full Text] [Related]
16. Effect of apraclonidine hydrochloride on the attack of Posner-Schlossman syndrome.
Hong C; Song KY
Korean J Ophthalmol; 1993 Jun; 7(1):28-33. PubMed ID: 7901442
[TBL] [Abstract][Full Text] [Related]
17. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
Chevrier RL; Assalian A; Duperré J; Lesk MR
Ophthalmic Surg Lasers; 1999 Mar; 30(3):199-204. PubMed ID: 10100253
[TBL] [Abstract][Full Text] [Related]
18. Short-term clinical trial evaluating the efficacy of the combination of apraclonidine 0.5% solution and betaxolol 0.25% suspension.
Lamberti G; Pignalosa B; Fusco R; Pignalosa G; Di Govanni A; Sebastiani A
Acta Ophthalmol Scand Suppl; 1997; (224):20-1. PubMed ID: 9589713
[No Abstract] [Full Text] [Related]
19. Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%.
Barnes SD; Campagna JA; Dirks MS; Doe EA
Ophthalmology; 1999 Oct; 106(10):2033-7. PubMed ID: 10519604
[TBL] [Abstract][Full Text] [Related]
20. Questions concerning the role of apraclonidine in the management of glaucoma.
Robin AL
Arch Ophthalmol; 1995 Jun; 113(6):712-4. PubMed ID: 7786208
[No Abstract] [Full Text] [Related]
[Next] [New Search]
